66.37
Cidara Therapeutics Inc stock is traded at $66.37, with a volume of 558.36K.
It is down -1.66% in the last 24 hours and up +7.87% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$67.49
Open:
$67.94
24h Volume:
558.36K
Relative Volume:
0.79
Market Cap:
$1.68B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-5.9632
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+1.77%
1M Performance:
+7.87%
6M Performance:
+208.12%
1Y Performance:
+410.54%
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CDTX
Cidara Therapeutics Inc
|
66.37 | 1.60B | 302.00K | -117.10M | -129.13M | -11.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-18-25 | Resumed | H.C. Wainwright | Buy |
Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
Nov-08-24 | Initiated | Guggenheim | Buy |
Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-03-21 | Resumed | H.C. Wainwright | Buy |
Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
Mar-04-21 | Initiated | Aegis Capital | Buy |
Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
Jul-26-18 | Initiated | Citigroup | Buy |
Apr-21-17 | Initiated | Raymond James | Strong Buy |
Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
Apr-11-17 | Resumed | Wedbush | Outperform |
Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
Dec-21-16 | Resumed | Leerink Partners | Outperform |
Dec-19-16 | Initiated | H.C. Wainwright | Buy |
Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
May-11-15 | Initiated | Jefferies | Buy |
May-11-15 | Initiated | Leerink Partners | Outperform |
May-11-15 | Initiated | Needham | Buy |
May-11-15 | Initiated | Wedbush | Outperform |
Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Cidara Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Pullbacks & Momentum Based Trading Ideas - beatles.ru
Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN
Will Cidara Therapeutics Inc. bounce back from current supportGold Moves & Capital Efficiency Focused Strategies - Newser
Comparing Cidara Therapeutics Inc. in custom built stock radarsPrice Action & Daily Stock Momentum Reports - Newser
What Fibonacci levels say about Cidara Therapeutics Inc. rebound2025 Volatility Report & Fast Entry and Exit Trade Plans - Newser
Is Cidara Therapeutics Inc. a candidate for recovery playAnalyst Downgrade & High Conviction Buy Zone Alerts - Newser
What MACD and RSI say about Cidara Therapeutics Inc.2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
What does recent volatility data suggest for Cidara Therapeutics Inc.Index Update & Fast Momentum Entry Tips - Newser
Is Cidara Therapeutics Inc. trending in predictive chart models2025 Bull vs Bear & Short-Term Trading Alerts - Newser
Comparing LakeShore Biopharma (NASDAQ:LSB) and Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionQuarterly Market Review & Stepwise Trade Execution Plans - Newser
Published on: 2025-08-15 18:00:40 - Newser
Cidara Therapeutics Inc. stock trend outlook and recovery path2025 Technical Overview & Fast Momentum Stock Entry Tips - Newser
Cidara Therapeutics: A High-Conviction Biotech Play with Clear Path to FDA Phase 3 and Market Disruption - AInvest
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX) - Seeking Alpha
Fund Update: MORGAN STANLEY added 875,198 shares of CIDARA THERAPEUTICS (CDTX) to their portfolio - Quiver Quantitative
Analyzing recovery setups for Cidara Therapeutics Inc. investorsEarnings Overview Summary & AI Powered Buy/Sell Recommendations - Newser
Published on: 2025-08-15 04:34:11 - Newser
Will Cidara Therapeutics Inc. stock split in the near future2025 Performance Recap & Risk Managed Trade Strategies - Newser
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN
What recovery options are there for Cidara Therapeutics Inc.July 2025 Short Interest & Low Risk High Reward Ideas - Newser
Cidara (CDTX) Q2 Cash Surges 163% - AOL.com
Cidara Therapeutics Inc. Pullback Analyzed — Is It Time to ExitMarket Entry and Exit Point Tips From Traders - beatles.ru
JMP Securities Raises Cidara Therapeutics (NASDAQ:CDTX) Price Target to $66.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at Needham & Company LLC - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 - Defense World
A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛
Cidara Therapeutics 2024 Q2 Earnings Net Loss Widens by 569.5% - AInvest
What moving averages say about Cidara Therapeutics Inc.Free Smart Trade Plans With Risk Protection - Newser
Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks
Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada
Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize
Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks
Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com
Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate
Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... By GuruFocus - Investing.com Canada
Cidara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cidara Therapeutics 2024 Q2 Earnings Deepened Losses Amid Strong Clinical Progress - AInvest
Transcript : Cidara Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82) - TipRanks
Cidara Therapeutics Q2 net loss narrows - MarketScreener
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cidara Therapeutics Inc Stock (CDTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):